Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/febs.15521 http://scihub22266oqcxt.onion/10.1111/febs.15521 32790936!7436654!32790936     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32790936&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32790936.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       FEBS+J 2020 ; 287 (17): 3656-3663 Nephropedia Template TP {{tp|p=32790936|t=2020. Nicotine and the nicotinic cholinergic system in COVID-19 |pdf=|usr=}}{{32790936}} gab.com Text Nicotine and the nicotinic cholinergic system in COVID-19 JO: FEBS J http://www.kidney.de/pget.php?&tw=1&pmid=32790936 #FOAvip There is an urgent need to address the devastating pandemic, COVID-19, caused by SARS-CoV-2. The efforts to understand the details of this disease in hope of providing effective treatments are commendable. It is clear now that the virus can cause far more damage in patients with comorbid conditions-particularly in those with respiratory, cardiovascular, or immune-compromised system-than in patients without such comorbidities. Drug use can further exacerbate the condition. In this regard, the ill effects of smoking are amply documented, and no doubt can be a confounding factor in COVID-19 progression. Although conflicting hypotheses on the potential role of nicotine in COVID-19 pathology have recently been offered, we believe that nicotine itself, through its interaction with the nicotinic cholinergic system, as well as ACE2, may not only be of use in a variety of neuropsychiatric and neurodegenerative diseases, but may also be of potential use in COVID-19. Thus, on one hand, while we strongly support smoking cessation as a means of harm reduction associated with COVID-19, on the other hand, we support a potential therapeutic role for nicotine, nicotinic agonists, or positive allosteric modulators of nicotinic cholinergic receptors in COVID-19, owing to their varied effects including mood regulation, anti-inflammatory, and purported interference with SARS-CoV-2 entry and/or replication. Twit Text FOAVip Nicotine and the nicotinic cholinergic system in COVID-19 ????FEBS J http://www.kidney.de/pget.php?&tw=1&pmid=32790936 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32790936 #FOAvip English Wikipedia <ref>{{Cite pmid|32790936}}</ref> Nicotine and the nicotinic cholinergic system in COVID-19 #MMPMID32790936 Tizabi Y; Getachew B; Copeland RL; Aschner M FEBS J 2020[Sep]; 287 (17): 3656-3663 PMID32790936show ga There is an urgent need to address the devastating pandemic, COVID-19, caused by SARS-CoV-2. The efforts to understand the details of this disease in hope of providing effective treatments are commendable. It is clear now that the virus can cause far more damage in patients with comorbid conditions-particularly in those with respiratory, cardiovascular, or immune-compromised system-than in patients without such comorbidities. Drug use can further exacerbate the condition. In this regard, the ill effects of smoking are amply documented, and no doubt can be a confounding factor in COVID-19 progression. Although conflicting hypotheses on the potential role of nicotine in COVID-19 pathology have recently been offered, we believe that nicotine itself, through its interaction with the nicotinic cholinergic system, as well as ACE2, may not only be of use in a variety of neuropsychiatric and neurodegenerative diseases, but may also be of potential use in COVID-19. Thus, on one hand, while we strongly support smoking cessation as a means of harm reduction associated with COVID-19, on the other hand, we support a potential therapeutic role for nicotine, nicotinic agonists, or positive allosteric modulators of nicotinic cholinergic receptors in COVID-19, owing to their varied effects including mood regulation, anti-inflammatory, and purported interference with SARS-CoV-2 entry and/or replication. |Angiotensin-Converting Enzyme 2/*genetics/immunology[MESH] |COVID-19/genetics/immunology/*metabolism/virology[MESH] |Cytokine Release Syndrome/genetics/immunology/*metabolism/virology[MESH] |Gene Expression Regulation[MESH] |Host-Pathogen Interactions/drug effects/genetics[MESH] |Humans[MESH] |Lung/drug effects/metabolism/pathology/virology[MESH] |Nicotine/*pharmacology[MESH] |Receptors, Nicotinic/*genetics/immunology[MESH] |Receptors, Virus/genetics/immunology[MESH] |SARS-CoV-2/immunology/pathogenicity[MESH] |Severity of Illness Index[MESH] |Signal Transduction[MESH] |Smoking/genetics/immunology/*metabolism[MESH]Nicotine and the nicotinic cholinergic system in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing